Table 2.
Patients characteristics
| Variable | n |
|---|---|
| n (%) | 89 |
| Age, median (IQR) | 71 (65-74.5) |
| Time (months) to recurrence from primary treatment, median (IQR) | 83 (64-110) |
| PSA pre-HIFU, median (IQR) | 5.8 (3.8-8) |
| PSA DT pre-HIFU in months, median (IQR) | 11.8 (7.5-17.5) |
| MRI tumor stage (%) | |
| T2 | 66 (74) |
| T3 | 23 (36) |
| Prostate volume, median, IQR) | 26 (19-33.75) |
| Biopsy type pre-HIFU n (%) | |
| TPM | 69 (78) |
| TRUS | 20 (22) |
| ISUP grade pre-HIFU, n (%) | |
| 1 | 3 (3) |
| 2 | 46 (52) |
| 3 | 25 (28) |
| 4 | 9 (10) |
| 5 | 6 (7) |
| D'Amico risk group pre-HIFU, n (%) | |
| Low | 1 (1) |
| Medium | 36 (40) |
| High | 38 (43) |
| Tumour location pre-HIFU mpMRI, n (%) | |
| Posterior | 71 (80) |
| Anterior | 13 (15) |
| Both | 2 (29 |
| Type of HIFU, n (%) | |
| Focal ablation | 62 (70) |
| Hemi-ablation | 27 (30) |
| Neo-adjuvant ADT pre-HIFU n (%) | |
| No | 50 (56) |
| Yes | 39 (44) |